WorkWebsite

Oral Biolife: making bone loss reversible.

A regenerative-medicine startup with a genuinely first-in-class idea: bone is piezoelectric, and that physics can be harnessed to regrow it, no drugs, no biologics. The science is elegant and easy to make sound like science fiction. The site's job is to make the mechanism read as inevitable, not implausible.

Client: Oral Biolife (OBL)
Sector: Biotech / Regenerative Medicine
Role: Brand & Site Direction
Year: 2025

00The opening

Plant the flag in the first second.

“Redefining Bone Regeneration.” The hero opens on the category claim over a dark, almost geological field — two buttons, nothing else. No mechanism, no hedging. A page that names the territory it intends to own before it explains a thing.

01The problem

Break the rule you’re about to rewrite.

“Bone loss is irreversible. Until it isn’t.” The page states the accepted clinical truth, then turns it in three words. The whole pitch compressed into a contradiction you can’t unread.

02The mechanism

Make the physics the hero.

“Bone is naturally piezoelectric. We are the first to harness these physics clinically.” The mechanism isn’t a drug or a biologic — it’s a property of bone itself. Stated plainly, the science sounds less like a bet and more like an inevitability.

03How it works

Three verbs. No external energy.

Convert, Activate, Regenerate — each in its own numbered cell, then the disqualifier: “No external energy. No drugs. No biologics.” The restraint is the claim. What it refuses to need is the proof that it works.

04The proof

Bound the number before it’s doubted.

“100% bone regeneration in pre-clinical models.” The figure is enormous, so the page immediately fences it in — canine ligature model, multi-species confirmation, clean safety profile. A 100% that names its own limits is one you believe.

05The pipeline

Show programs, not a platform.

Two named programs: Ambrilux™ for periodontal bone loss (preclinical, FIH 2026) and a veterinary dental gel already commercial. Human and animal, shipping and ahead. Specific indications and stages, not a platform promising everything to everyone.

06The vision

Let the founder widen the frame.

The closing argument zooms out — oral inflammation tied to heart, metabolism, longevity — signed by the founder. It reframes a dental company as a systemic-health one without overclaiming. Ambition stated as a direction, not a boast.

07The close

End quiet, ask small.

“Follow our journey.” One email field, one button, no hard sell. A company this early earns attention before it asks for anything bigger. The close matches the confidence of the open.

oralbiolife.com